Savara (NASDAQ:SVRA) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS

Key Points

• Savara reported a quarterly loss of $0.16 per share, missing analysts’ consensus estimate by $0.02.
• Shares fell $0.16 to $5.57 during Tuesday trading. The company has a $1.14 billion market capitalization, while institutional investors own 87.93% of its stock.
• Analyst sentiment remains generally positive, with a “Moderate Buy” consensus and an average price target of $10.14 versus the current share price; Savara’s lead candidate, Molgradex, is under regulatory review for autoimmune pulmonary alveolar proteinosis.

Savara (NASDAQ:SVRA - Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.02), FiscalAI reports.

Savara Stock Performance

NASDAQ SVRA traded down $0.16 during trading hours on Tuesday, hitting $5.57. 1,263,485 shares of the company's stock traded hands, compared to its average volume of 1,620,952. Savara has a 52 week low of $2.43 and a 52 week high of $7.01. The firm has a market capitalization of $1.14 billion, a P/E ratio of -9.95 and a beta of 0.29. The company has a current ratio of 13.47, a quick ratio of 13.47 and a debt-to-equity ratio of 0.17. The business's fifty day moving average price is $5.63 and its two-hundred day moving average price is $5.50.

Institutional Investors Weigh In On Savara

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Prudential Financial Inc. bought a new stake in Savara during the second quarter valued at about $30,000. BNP Paribas Financial Markets lifted its holdings in Savara by 52.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company's stock worth $31,000 after purchasing an additional 4,626 shares in the last quarter. Brevan Howard Capital Management LP bought a new position in Savara in the 2nd quarter worth approximately $33,000. Russell Investments Group Ltd. grew its holdings in Savara by 930.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company's stock valued at $37,000 after buying an additional 9,463 shares in the last quarter. Finally, CIBC Bancorp USA Inc. purchased a new stake in Savara during the 3rd quarter valued at approximately $44,000. Institutional investors own 87.93% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on SVRA shares. Oppenheimer initiated coverage on shares of Savara in a research note on Friday, April 24th. They set an "outperform" rating and a $11.00 target price on the stock. Wall Street Zen upgraded shares of Savara from a "sell" rating to a "hold" rating in a research note on Saturday, June 13th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Savara in a report on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $10.14.

Savara Company Profile

Savara Inc NASDAQ: SVRA is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company's lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source